2cureX AB (Ticker: 2CUREX) today announces continued momentum in its strategic execution, with the share price surging more than 1,000% over the past few months. This rapid appreciation reflects market recognition of the company’s execution under its growth strategy, Operation Twin Code, which is now fully active.

2cureX invites to an on-line webcast at 14:00 (CET) on 2nd July 2025:
Link for participation (registration is not required): https://youtube.com/live/dFHB-b0qt4

Newly appointed CEO Nathaniel Hutley gives a presentation of the “new” 2cureX after the AGM, held at the 26th of June. After the presentation there will be a moderated Q&A. Viewers can ask their questions in the live chat or prior to the webcast by sending an email with 2cureX in the subject field to studio@direkt.se

Outlook
Rather than focusing on short-term test volume, 2cureX has spent the past quarter building and activating the infrastructure required to scale globally. With a lean cross-border operating model between 2cureX AB (Sweden) and 2cureX AS (Denmark), the company is laying the foundation for exponential delivery—not of dozens of tests, but millions.

AI-Powered, Patient-Focused
As part of its execution, 2cureX has integrated AI-powered bots into its sales and patient engagement workflows, enabling high-speed, direct-to-patient interaction at scale with minimal human resource footprint. This positions the company for rapid expansion while maintaining operational discipline.

Nathaniel Hutley, CEO, commented:
“We haven’t built this company to sell 20 tests—we’re building it to deliver a million. Operation Twin Code is live, lean, and now proving its value. We are executing at every level: structurally, commercially, and now technologically. And the market has taken notice.”

Shareholder Meeting – July 2rd, Sweden
Mr. Hutley will travel to Stockholm on July 2rd to meet with shareholders and stakeholders. Topics will include recent progress, strategic planning, and an open conversation around a future health dividend—a potential model where shareholders who are also patients may receive direct medical benefit.

“We’ve started the conversation about a different kind of return—one that includes health outcomes. We believe our shareholders will help us lead that dialogue.”

For more information about 2cureX:

Nathaniel Hutley, Interim CEO
E-mail: NH@2curex.com
Telephone: +44 (776) 514 1346

About 2cureX

2cureX is redefining cancer treatment selection through functional precision oncology. Its proprietary IndiTreat® test family creates thousands of 3D tumor replicas—called tumoroids—from a patient’s biopsy to identify which chemotherapy or targeted drugs that are most effective for that specific tumor. The result: real data to drive real decisions.
The first three IndiTreat® tests target patients with metastatic colorectal cancer:
                •  IndiTreat® Start (first-line therapy)
                •  IndiTreat® Extend & Explore (third-line options)

New IndiTreat® versions are in development for earlier-stage colorectal cancer and other GI cancers.
Despite global cancer IVD spending exceeding $17.5 billion annually, fewer than 1 in 3 treatments are guided by a predictive test. IndiTreat® aims to close that gap—bringing clarity to treatment selection and precision to every patient.

2cureX AB is listed on Nasdaq First North Growth Market under the ticker 2CUREX, with operational delivery in partnership with 2cureX A/S in Denmark. This cross-border structure powers the company’s new commercial strategy, Operation Twin Code—now live.

Attachments

CEO Nathaniel Hutley presents latest news from 2cureX on July 2nd 2025.

Läs mer på MFN